3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Breast
1
Conditions
Brain Neoplasms
3
Neoplasm Metastasis
2
Lung Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Oligodendroglioma
1
Gliosarcoma
1
Glioblastoma
1
Central Nervous System Neoplasms
1
Breast Neoplasms
1
Astrocytoma
1
Adenocarcinoma of Lung
1
Interventions
Trastuzumab
597
Paclitaxel
562
Cyclophosphamide
545
Docetaxel
479
Capecitabine
388
Letrozole
350
Fulvestrant
311
Doxorubicin
285
Carboplatin
277
Tamoxifen
257
Anastrozole
219
exemestane
211
Epirubicin
210
Radiotherapy
197
Bevacizumab
189
pertuzumab
177
Gemcitabine
163
Vinorelbine
162
pembrolizumab
161
Lapatinib
161
palbociclib
152
Exercise
132
Fluorouracil
118
Albumin-Bound Paclitaxel
116
eribulin
108
Magnetic Resonance Spectroscopy
108
130-nm albumin-bound paclitaxel
107
Everolimus
103
Taxes
96
Cisplatin
92
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Breast Neoplasms
×
efaproxiral
×
Clear all
NCT00083304
2013-05-10
ENRICH
Spectrum Pharmaceuticals, Inc
Phase 3
Completed
368 enrolled